Inventor · disambiguated record
David John Kopecky
Also filed as: KOPECKY DAVID J · KOPECKY DAVID JOHN
30 granted patents·13 pending applications·476 citations·filing 2003–2025
97Inventor score
Top patents by PatentIndex Score
43 records- 0198US11905281B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2020·Granted Feb 20, 2024·13 cites·16 claims
- 0298US11766436B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2021·Granted Sep 26, 2023·11 cites·19 claims
- 0398US11090304B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Aug 17, 2021·33 cites·3 claims
- 0498US10532042B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2017·Granted Jan 14, 2020·49 cites·13 claims
- 0598US10519146B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2018·Granted Dec 31, 2019·81 cites·33 claims
- 0698US9573936B2Triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted Feb 21, 2017·19 cites·56 claims
- 0797US11285135B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Mar 29, 2022·20 cites·16 claims
- 0897US10221162B2Triazole agonists of the APJ receptorAMGEN INC·Filed 2018·Granted Mar 5, 2019·12 cites·22 claims
- 0997US10058550B2Methods of treating heart failureAMGEN INC·Filed 2017·Granted Aug 28, 2018·13 cites·81 claims
- 1097US9868721B2Triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted Jan 16, 2018·14 cites·60 claims
- 1197US9745286B2Triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted Aug 29, 2017·16 cites·52 claims
- 1297US9656998B2Intermediates for preparing triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted May 23, 2017·14 cites·16 claims
- 1395US9845310B2Intermediates for preparing triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted Dec 19, 2017·14 cites·16 claims
- 1495US9751864B2Methods for preparing triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted Sep 5, 2017·14 cites·28 claims
- 1595US9656997B2Triazole agonists of the APJ receptorAMGEN INC·Filed 2016·Granted May 23, 2017·16 cites·46 claims
- 1693US12440491B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2023·Granted Oct 14, 2025·1 cites·4 claims
- 1793US7199119B2Antiinflammation agentsAMGEN INC·Filed 2003·Granted Apr 3, 2007·75 cites·11 claims
- 1890US10150760B2Compounds for use in preparing heterocyclic triazole agonists of the APJ receptorAMGEN INC·Filed 2018·Granted Dec 11, 2018·8 cites·29 claims
- 1989US9988369B2Heterocyclic triazole compounds as agonists of the APJ receptorAMGEN INC·Filed 2017·Granted Jun 5, 2018·8 cites·67 claims
- 2088US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 2188US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 2288US2025381187A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2025·Application pending·0 cites
- 2387US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 2486US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 2586US7635695B2Antiinflammation agentsAMGEN INC·Filed 2007·Granted Dec 22, 2009·10 cites·20 claims
- 2685US2025362134A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2025·Application pending·0 cites
- 2784US2024174660A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2023·Application pending·0 cites
- 2882US2025057817A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2024·Application pending·0 cites
- 2980US11046680B1Heteroaryl-substituted triazoles as APJ receptor agonistsAMGEN INC·Filed 2017·Granted Jun 29, 2021·2 cites·33 claims
- 3080US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 3178US7358250B2Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activityAMGEN INC·Filed 2005·Granted Apr 15, 2008·4 cites·22 claims
- 3274US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 3374US2022168280A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2022·Application pending·0 cites
- 3473US11020395B2Cycloalkyl substituted triazole compounds as agonists of the APJ receptorAMGEN INC·Filed 2017·Granted Jun 1, 2021·1 cites·26 claims
- 3570US10736883B2Triazole furan compounds as agonists of the APJ receptorAMGEN INC·Filed 2017·Granted Aug 11, 2020·1 cites·25 claims
- 3670US2020055845A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2019·Application pending·0 cites
- 3767US7112606B2Heterocyclic arylsulfonamidobenzylic compoundsAMGEN INC·Filed 2003·Granted Sep 26, 2006·3 cites·8 claims
- 3867US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 3965US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 4064US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 4153US7473703B2Heterocyclic arylsulfonamidobenzylic compoundsAMGEN INC·Filed 2006·Granted Jan 6, 2009·0 cites·9 claims
- 4243US7763624B2Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitorsAMGEN INC·Filed 2006·Granted Jul 27, 2010·0 cites·34 claims
- 4343US2006264424A1Arylsulfonamidobenzylic compoundsTULARIK INC·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →